Role of perioperative immunotherapy in localized renal cell carcinoma

Jasmeet Kaur; Goutham Patil; Daniel M. Geynisman; Pooja Ghatalia

doi:10.1177/17588359231181497

Role of perioperative immunotherapy in localized renal cell carcinoma

Jasmeet Kaur, Goutham Patil, Daniel M. Geynisman, Pooja Ghatalia

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Immunotherapy has proven effective in metastatic renal cell carcinoma (RCC). The current standard of treatment in localized RCC is partial or complete nephrectomy. However, after surgery, there is a high recurrence rate and survival rates ranging from 53% to 85% depending on the stage of disease at presentation. Given clinical response to immunotherapies in metastatic RCC, these therapies are being tested as monotherapy and in combination with vascular endothelial growth factor receptor tyrosine kinase inhibitors in the (neo)adjuvant setting. Here we describe the current landscape of these treatments in localized RCC.

Original language	English
Journal	Therapeutic Advances in Medical Oncology
Volume	15
DOIs	https://doi.org/10.1177/17588359231181497
State	Published - Jan 1 2023

Keywords

adjuvant
immunotherapy
kidney cancer
neoadjuvant
renal cell carcinoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/17588359231181497

Cite this

@article{8231630ee26d4c6087c781d5eceefd6f,

title = "Role of perioperative immunotherapy in localized renal cell carcinoma",

abstract = "Immunotherapy has proven effective in metastatic renal cell carcinoma (RCC). The current standard of treatment in localized RCC is partial or complete nephrectomy. However, after surgery, there is a high recurrence rate and survival rates ranging from 53% to 85% depending on the stage of disease at presentation. Given clinical response to immunotherapies in metastatic RCC, these therapies are being tested as monotherapy and in combination with vascular endothelial growth factor receptor tyrosine kinase inhibitors in the (neo)adjuvant setting. Here we describe the current landscape of these treatments in localized RCC.",

keywords = "adjuvant, immunotherapy, kidney cancer, neoadjuvant, renal cell carcinoma",

author = "Jasmeet Kaur and Goutham Patil and Geynisman, {Daniel M.} and Pooja Ghatalia",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2023.",

year = "2023",

month = jan,

day = "1",

doi = "10.1177/17588359231181497",

language = "English",

volume = "15",

journal = "Therapeutic Advances in Medical Oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Role of perioperative immunotherapy in localized renal cell carcinoma

AU - Kaur, Jasmeet

AU - Patil, Goutham

AU - Geynisman, Daniel M.

AU - Ghatalia, Pooja

N1 - Publisher Copyright: © The Author(s), 2023.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Immunotherapy has proven effective in metastatic renal cell carcinoma (RCC). The current standard of treatment in localized RCC is partial or complete nephrectomy. However, after surgery, there is a high recurrence rate and survival rates ranging from 53% to 85% depending on the stage of disease at presentation. Given clinical response to immunotherapies in metastatic RCC, these therapies are being tested as monotherapy and in combination with vascular endothelial growth factor receptor tyrosine kinase inhibitors in the (neo)adjuvant setting. Here we describe the current landscape of these treatments in localized RCC.

AB - Immunotherapy has proven effective in metastatic renal cell carcinoma (RCC). The current standard of treatment in localized RCC is partial or complete nephrectomy. However, after surgery, there is a high recurrence rate and survival rates ranging from 53% to 85% depending on the stage of disease at presentation. Given clinical response to immunotherapies in metastatic RCC, these therapies are being tested as monotherapy and in combination with vascular endothelial growth factor receptor tyrosine kinase inhibitors in the (neo)adjuvant setting. Here we describe the current landscape of these treatments in localized RCC.

KW - adjuvant

KW - immunotherapy

KW - kidney cancer

KW - neoadjuvant

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85166592282&partnerID=8YFLogxK

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:001036775000001&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1177/17588359231181497

DO - 10.1177/17588359231181497

M3 - Review article

C2 - 37529159

SN - 1758-8340

VL - 15

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

ER -

Role of perioperative immunotherapy in localized renal cell carcinoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

New Study Findings from Fox Chase Cancer Center Illuminate Research in Carcinomas (Role of perioperative immunotherapy in localized renal cell carcinoma)

Cite this

Role of perioperative immunotherapy in localized renal cell carcinoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Press/Media

New Study Findings from Fox Chase Cancer Center Illuminate Research in Carcinomas (Role of perioperative immunotherapy in localized renal cell carcinoma)

Cite this